USD10
APLS Shares
About Apellis PharmaceuticalsApellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).
USD10
APLS Shares
About Apellis PharmaceuticalsApellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).
Stats
TRADING WINDOW
Closed
OPENS AT
Mar 25 at 1:30 PM GMT+0
MARKET CAP
$2.24B
OPEN PRICE
Not enough data
LOW (1Y)
$16.10
HIGH (1Y)
$30.48
LOW (24H)
$16.84
HIGH (24H)
$17.70
VOLUME (24H)
$18.43K
99.42%
Price history
Time | Price | Change |
|---|---|---|
Today | Not enough data | Not enough data |
1 Day | $17.50 | |
1 Week | $18.04 | |
1 Month | $21.13 | |
1 Year | $23.79 |